according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

# SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Vaniprevir Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-

stance/Mixture

: Pharmaceutical

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Kilsheelan

Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person

responsible for the SDS

EHSDATASTEWARD@msd.com

### 1.4 Emergency telephone number

+1-908-423-6000

### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

#### Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - repeated exposure, Category 2

H373: May cause damage to organs through prolonged or repeated exposure.

2.2 Label elements

#### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

Signal word : Warning

Hazard statements : H373 May cause damage to organs through prolonged or

repeated exposure.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

Precautionary statements : Prevention:

P260 Do not breathe dust.

Response:

P314 Get medical advice/ attention if you feel unwell.

Hazardous components which must be listed on the label:

Vaniprevir

#### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

#### **SECTION 3: Composition/information on ingredients**

#### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Vaniprevir	923590-37-8	STOT RE 2; H373 (gallbladder, Liver)	>= 10 - < 20

For explanation of abbreviations see section 16.

#### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

Risks : May cause damage to organs through prolonged or repeated

exposure.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

#### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

#### **SECTION 5: Firefighting measures**

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

#### 5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth- :

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

#### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

# **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

and bonding, or inert atmospheres.

Local/Total ventilation

Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

#### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

#### **SECTION 8: Exposure controls/personal protection**

#### 8.1 Control parameters

#### **Occupational Exposure Limits**

Dust 5 mg/m3

Value type (Form of exposure): TWA (respirable dust)

Basis: FOR-2011-12-06-1358

10 mg/m3

Value type (Form of exposure): TWA (total dust)

Basis: FOR-2011-12-06-1358

Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		
Vaniprevir	923590-37-	TWA	300 μg/m3	Internal
	8			

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

Substance name	End Use	Exposure routes	Potential health effects	Value
Polyethylene glycol castor oil	Workers	Inhalation	Long-term systemic effects	16,4 mg/m3
	Workers	Skin contact	Long-term systemic effects	4,67 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	2,9 mg/m3
	Consumers	Skin contact	Long-term systemic effects	1,67 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	1,67 mg/kg bw/day

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Polyethylene glycol castor oil	Fresh water	0,000 mg/l
	Freshwater - intermittent	0,0661 mg/l
	Marine water	0,000 mg/l
	Marine water - intermittent	0,00661 mg/l
	Fresh water sediment	0,0129 mg/kg dry weight (d.w.)
	Marine sediment	0,00129 mg/kg dry weight (d.w.)
	Soil	0,00258 mg/kg dry weight (d.w.)

#### 8.2 Exposure controls

# **Engineering measures**

Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

# Personal protective equipment

Eye/face protection : Wear the following personal protective equipment:

Safety goggles

Equipment should conform to NS EN 166

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending

on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version **Revision Date:** SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

end of workday.

Skin and body protection

Skin should be washed after contact.

Respiratory protection If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to NS EN 143

Filter type Particulates type (P)

### **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

Physical state powder

Colour tan

Odour odourless

Odour Threshold No data available

Melting point/freezing point No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point No data available

Auto-ignition temperature No data available

Decomposition temperature No data available

No data available pΗ

Viscosity

Viscosity, dynamic No data available

Viscosity, kinematic No data available

Solubility(ies)

Water solubility No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

Partition coefficient: n-

octanol/water

: No data available

Vapour pressure : No data available

Density : 1 g/cm<sup>3</sup>

Relative vapour density : No data available

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

### **SECTION 10: Stability and reactivity**

#### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

#### **SECTION 11: Toxicological information**

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

**Acute toxicity** 

Not classified based on available information.

**Components:** 

Vaniprevir:

Acute oral toxicity : LD50 (Rat): > 750 mg/kg

Remarks: No adverse effect has been observed in acute tox-

icity tests.

LD0 (Dog): > 300 mg/kg

Remarks: No adverse effect has been observed in acute tox-

icity tests.

LD50 (Mouse): > 2.000 mg/kg

Remarks: No mortality observed at this dose.

Skin corrosion/irritation

Not classified based on available information.

Components:

Vaniprevir:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

**Components:** 

Vaniprevir:

Species : Bovine cornea

Method : Bovine cornea (BCOP)
Result : Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

**Components:** 

Vaniprevir:

Test Type : Local lymph node assay (LLNA)

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

Species : Mouse Result : negative

# Germ cell mutagenicity

Not classified based on available information.

#### **Components:**

Vaniprevir:

Genotoxicity in vitro : Test Type: Chromosomal aberration

Test system: Chinese hamster ovary cells

Result: negative

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Alkaline elution assay Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral

Result: negative

#### Carcinogenicity

Not classified based on available information.

#### **Components:**

Vaniprevir:

Species : Rat, male and female

Application Route : Oral

Activity duration : 104 Weeks

: >= 120 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Oral
Activity duration : 6 Months

: >= 300 mg/kg body weight

: 75 mg/kg body weight

Result : negative Target Organs : gallbladder

#### Reproductive toxicity

Not classified based on available information.

#### **Components:**

Vaniprevir:

Effects on fertility : Test Type: Fertility/early embryonic development

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

Species: Rat, male and female

Application Route: Oral

General Toxicity - Parent: NOAEL: >= 250 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Development Species: Rat, female

Application Route: Oral

General Toxicity Maternal: NOAEL: 120 mg/kg body weight Developmental Toxicity: LOAEC F1: 180 mg/kg body weight

Symptoms: No specific developmental abnormalities

Result: negative

Test Type: Development Species: Rabbit, female Application Route: Oral

General Toxicity Maternal: NOAEL: 120 mg/kg body weight Developmental Toxicity: NOAEL F1: >= 240 mg/kg body

weight

Symptoms: No specific developmental abnormalities

Result: negative

# STOT - single exposure

Not classified based on available information.

# STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

#### **Components:**

# Vaniprevir:

Exposure routes : Ingestion

Target Organs : gallbladder, Liver

Assessment : May cause damage to organs through prolonged or repeated

exposure.

#### Repeated dose toxicity

# **Components:**

### Vaniprevir:

Species : Rat
NOAEL : 120 mg/kg
LOAEL : 360 mg/kg
Application Route : Oral
Exposure time : 6 Months
Target Organs : Liver

Species : Dog
NOAEL : 15 mg/kg
LOAEL : 30 mg/kg
Application Route : Oral
Exposure time : 9 Months

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

**Target Organs** Liver, gallbladder

**Symptoms** Gastrointestinal disturbance

**Species** Mouse NOAEL 150 mg/kg LOAEL 300 mg/kg **Application Route** Oral Exposure time 90 d

Liver, Kidney, Gastrointestinal tract, Heart, gallbladder, Stom-Target Organs

### **Aspiration toxicity**

Not classified based on available information.

#### 11.2 Information on other hazards

### **Endocrine disrupting properties**

#### **Product:**

Assessment The substance/mixture does not contain components consid-

> ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

#### **Experience with human exposure**

#### **Components:**

Vaniprevir:

Ingestion Symptoms: stomach discomfort, Diarrhoea, Nausea, Head-

ache

#### **SECTION 12: Ecological information**

# 12.1 Toxicity

#### **Components:**

#### Vaniprevir:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 4 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

LC50 (Americamysis): > 4 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035 Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 4

mg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 4 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 1.000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 1.000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

#### 12.2 Persistence and degradability

#### **Components:**

Vaniprevir:

Biodegradability : Result: not rapidly degradable

Method: OECD Test Guideline 314

#### 12.3 Bioaccumulative potential

#### Components:

Vaniprevir:

Partition coefficient: n-

octanol/water

: log Pow: 4,12

#### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### **Product:**

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

#### 12.6 Endocrine disrupting properties

#### **Product:**

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

levels of 0.1% or higher.

#### 12.7 Other adverse effects

No data available

### **SECTION 13: Disposal considerations**

#### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

### 14.2 UN proper shipping name

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA : Not regulated as a dangerous good

#### 14.4 Packing group

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

ADN : Not regulated as a dangerous good
ADR : Not regulated as a dangerous good
RID : Not regulated as a dangerous good
IMDG : Not regulated as a dangerous good
IATA (Cargo) : Not regulated as a dangerous good
IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

#### **SECTION 15: Regulatory information**

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

: Not applicable

Not applicable

REACH - Restrictions on the manufacture, placing on

the market and use of certain dangerous substances,

mixtures and articles (Annex XVII)

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Regulation (EC) on substances that deplete the ozone : Not applicable

laver

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EU) No 649/2012 of the European Parlia: Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

#### Other regulations:

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

#### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

#### **SECTION 16: Other information**

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

**Full text of H-Statements** 

H373 : May cause damage to organs through prolonged or repeated

exposure if swallowed.

Full text of other abbreviations

STOT RE : Specific target organ toxicity - repeated exposure

FOR-2011-12-06-1358 : Norway. Occupational Exposure limits

FOR-2011-12-06-1358 / : Long term exposure limit

**TWA** 

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# Vaniprevir Formulation

Version Revision Date: SDS Number: Date of last issue: 06.04.2024 3.3 28.09.2024 25798-00025 Date of first issue: 27.10.2014

**Further information** 

Sheet

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture: Classification procedure:

STOT RE 2 H373 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN